Astrazeneca (AZN) Capital Expenditures (2009 - 2026)
Astrazeneca (AZN) posted quarterly Capital Expenditures of $1.9 billion for Q2 2026, up 22.41% year-over-year from $1.5 billion in Q2 2025, and up 439.49% quarter-over-quarter from -$547.0 million in Q1 2026.
Astrazeneca (AZN) Capital Expenditures (2009 - 2026) Analysis & Trends
Astrazeneca's Capital Expenditures history runs 17 years deep, the most recent figure standing at $1.9 billion for Q2 2026.
- In Q2 2026, Capital Expenditures rose 22.41% year-over-year to $1.9 billion; the TTM figure through Jun 2026 stood at $3.0 billion (down 20.44% YoY), while the FY2025 annual figure was $2.8 billion, up 46.05% from the prior year.
- Capital Expenditures for Q2 2026 stood at $1.9 billion, up from -$547.0 million in the prior quarter.
- The five-year high for Capital Expenditures was $4.6 billion in Q4 2025, with the low at -$2.9 billion in Q3 2025.
- The 5-year median for Capital Expenditures is -$261.5 million (2022), against an average of $361.1 million.
- Peak annual rise in Capital Expenditures reached 497.12% in 2025, while the deepest fall reached 586.33% in 2025.
- Astrazeneca's Capital Expenditures stood at -$253.0 million in 2022, then slipped by 6.72% to -$270.0 million in 2023, then jumped by 1262.96% to $3.1 billion in 2024, then jumped by 45.99% to $4.6 billion in 2025, then slumped by 59.49% to $1.9 billion in 2026.
- Business Quant data shows AZN's Capital Expenditures at $1.9 billion in Q2 2026, -$547.0 million in Q1 2026, and $4.6 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.51 Bn | 632.75 Bn | 17.26 Bn | 1.32 Bn |
| 2 | AbbVie | 470.67 Bn | 464.10 Bn | 12.70 Bn | 322.00 Mn |
| 3 | Merck | 378.00 Bn | 370.86 Bn | 12.21 Bn | 893.00 Mn |
| 4 | Novartis Ag | 303.24 Bn | 295.55 Bn | 11.24 Bn | 321.00 Mn |
| 5 | Astrazeneca | 257.85 Bn | 252.95 Bn | 12.86 Bn | 1.86 Bn |
| 6 | Amgen | 236.64 Bn | 222.65 Bn | 7.24 Bn | 513.00 Mn |
| 7 | Gilead Sciences | 182.27 Bn | 179.09 Bn | 6.22 Bn | 140.00 Mn |
| 8 | Pfizer | 159.46 Bn | 147.76 Bn | 10.94 Bn | 533.00 Mn |
| 9 | Gsk | 106.20 Bn | 102.03 Bn | 8.24 Bn | -440.07 Mn |
| 10 | Sanofi | 55.06 Bn | 47.68 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.86 Bn |
| Jun 30, 2026 | 1.86 Bn |
| Mar 31, 2026 | -547.00 Mn |
| Mar 31, 2026 | -547.00 Mn |
| Dec 31, 2025 | 4.58 Bn |
| Dec 31, 2025 | 4.58 Bn |
| Sep 30, 2025 | -2.86 Bn |
| Sep 30, 2025 | -2.86 Bn |
| Jun 30, 2025 | 1.52 Bn |
| Jun 30, 2025 | 1.52 Bn |
| Mar 31, 2025 | -429.00 Mn |
| Mar 31, 2025 | -429.00 Mn |
| Dec 31, 2024 | 3.14 Bn |
| Dec 31, 2024 | 3.14 Bn |
| Sep 30, 2024 | -417.00 Mn |
| Sep 30, 2024 | -417.00 Mn |
| Jun 30, 2024 | -382.00 Mn |
| Jun 30, 2024 | -382.00 Mn |
| Mar 31, 2024 | -417.00 Mn |
| Mar 31, 2024 | -417.00 Mn |